TL;DR
Get beauty and skincare favorites delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Galderma has agreed to acquire all of ZO Skin Health for $1.5 billion in cash, adding the physician-dispensed skincare brand to its portfolio. The deal is subject to regulatory approval and is expected to close in the fourth quarter of 2026 or early 2027.
Galderma has signed an agreement to acquire 100 percent of ZO Skin Health for US$1.5 billion in cash, adding the physician-dispensed skincare brand to its dermatology and medical aesthetics portfolio. The deal, which requires regulatory approval, is expected to close in the fourth quarter of 2026 or early 2027.
The transaction covers all of ZO Skin Health, which Galderma will buy from shareholders including Blackstone Tactical Opportunities and the Obagi family. The source report identifies the arrangement as an all-cash acquisition. It does not provide a breakdown of the purchase price or say whether the deal includes conditions beyond regulatory approval.
Founded by dermatologist Dr. Zein Obagi, ZO Skin Health is based in the United States and sells skincare products through professional and online channels. The company generated approximately US$330 million in net sales in the 12 months to June 2026, according to the report. That figure is a reported historical sales total; no comparison with a prior period or forecast is provided.
ZO operates in more than 40 countries and reaches customers through a network of over 16,500 physician, medical spa and online accounts. Galderma said the brand will complement its existing Cetaphil and Alastin businesses. It also plans to increase commercial investment to support ZO’s future growth, though the company has not disclosed an amount or a detailed spending plan.
A Broader Professional Skincare Portfolio
The acquisition would give Galderma another established brand in professional skincare, alongside Cetaphil and Alastin. ZO’s network of physician and medical spa accounts could extend the company’s reach among dermatologists and aesthetic practitioners, while its presence in more than 40 countries offers an existing international distribution footprint.
Galderma also links the purchase to its medical aesthetics business, which includes injectable treatments. The company sees opportunities to develop distribution and product activity across its skincare and aesthetics businesses. Those are strategic aims, not confirmed results: the source report gives no specific product plans, revenue targets, or expected cost savings from combining the businesses.
For ZO, ownership by Galderma could bring additional commercial investment and access to a larger dermatology-focused company. The size of the deal, relative to ZO’s reported sales, makes it a significant portfolio expansion for Galderma. However, the available information does not explain how the purchase will be financed or how it may affect Galderma’s financial outlook.
As an affiliate, we earn on qualifying purchases.
How ZO Fits Galderma’s Business
Galderma operates in dermatology and medical aesthetics and already owns Cetaphil and Alastin, according to the source report. ZO adds a brand founded by a dermatologist and sold through physician, medical spa and online accounts. The deal therefore brings Galderma a business with an existing professional channel and international reach.
The acquisition is an agreement, not a completed transfer of ownership. Its planned timing—the fourth quarter of 2026 or early 2027—depends on regulatory approval. The report does not identify the regulators involved or describe any review timetable. Until the transaction closes, ZO remains with its current shareholders.
Approval and Deal Terms Ahead
The transaction remains subject to regulatory approval, and the parties have not completed the transfer. The source report does not name the reviewing authorities, say whether any other closing conditions apply, or indicate whether regulators have raised concerns.
Other details are also not available in the report, including the acquisition’s financing, any planned leadership or operational changes, and how Galderma will integrate ZO’s sales channels and products. The stated plan for greater commercial investment has no disclosed budget or timetable. The reported US$330 million in sales covers the 12 months to June 2026; no profit figures, year-over-year comparison or forward guidance are given.
Regulatory Review Sets the Timeline
The next major step is regulatory review. If approval is granted and the other transaction conditions are met, Galderma expects the acquisition to close in the fourth quarter of 2026 or early 2027. The company has not provided a more precise closing date.
Further information may clarify the transaction’s financing, integration plans and the scale of the promised commercial investment. Until closing, the deal remains pending and ZO Skin Health continues under its current ownership.
Key Questions
How much is Galderma paying for ZO Skin Health?
Galderma agreed to pay US$1.5 billion in an all-cash transaction for all of ZO Skin Health.
Who currently owns ZO Skin Health?
The stated sellers include Blackstone Tactical Opportunities and the Obagi family. The agreement covers 100 percent of the company, but ownership will transfer only if the deal closes.
When is the acquisition expected to close?
Galderma expects the deal to close in the fourth quarter of 2026 or early 2027, subject to regulatory approval.
How large is ZO Skin Health’s business?
ZO generated approximately US$330 million in net sales in the 12 months to June 2026, according to the source report. It operates in more than 40 countries and serves over 16,500 physician, medical spa and online accounts.
What remains uncertain about the deal?
Regulatory approval is still pending. The report does not detail the financing, closing conditions beyond approval, integration plans or the amount Galderma expects to invest in ZO’s commercial growth.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
